Join us on December 14 for our Patient-Focused Sessions on Multiple Myeloma, taking place in Charlotte, NC! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

ASCO 2019

Highlights from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, where oncology professionals, patients and advocates from around the world gather to share the latest advances in the field.
Jessica Skarzynski
The executive director of the Cancer Policy Institute at the Cancer Support Community offers some candid advice for individuals who may be facing a new cancer diagnosis.
Beth Fand Incollingo
The merging of MyLifeLine.org with Cancer Support Community facilitates more comprehensive social and emotional support for patients and caregivers affected by cancer.
Kristie L. Kahl
Treatment with fedratinib may lead to clinically meaningful responses among patients with myelofibrosis who were previously treated with Jakafi, according to an updated analysis of the phase 2 JAKARTA2 study.
Beth Fand Incollingo
Given with each dose of chemotherapy, trilaciclib temporarily puts bone marrow to sleep, helping to prevent fevers, infections and hospital stays in patients with small cell lung cancer.
Brielle Benyon
Patients with breast cancer can still enroll in a clinical trial that is seeking to find the cause behind cardiac toxicity related to anthracycline-based treatment.
Katie Kosko
Researchers examined what goes into treatment decision-making for patients with multiple myeloma.
Lowell Hart
With new ways to treat chemotherapy-induced side effects, it seems that chemotherapy, combined with checkpoint inhibitors, is here to stay for the foreseeable future, according to one expert.
Jessica Skarzynski
With a wealth of drugs available for the treatment of liver cancer, one expert explained how combination therapy may be where the future is headed.
R. Donald Harvey
One expert weighs the benefits and drawbacks of expanding clinical trials to be more inclusive and reflective of the general patient population with cancer.
Sara Karlovitch
A breast cancer survivor and hereditary cancer expert discussed how patients can find accurate information about genetic mutations.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×